ClinicalTrials.gg
RecruitingNCT06378606cogntionUpdated Apr 22, 2024

Effect of Technology on Cognitive Function in Elderly

An interventional study of cognitive therapy in Cognitive Impairment, sponsored by Nourhan Hesham Ali. Recruiting at 1 site in Egypt. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Nourhan Hesham Ali · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Jul 2023, registered Feb 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Cognitive Dysfunction with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Cognitive Dysfunction · Egypt.

Planned enrollment
9th of 18
60 · median 60
Started
2023
with 2 others
No phase
11 of 29
1 open now
Registered
20th of 29
by date

Among the 29 studies in Cognitive Dysfunction with a site in Egypt, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2023, is one of 11 with no phase, and was the 20th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

7 of the 29 studies in Cognitive Dysfunction with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Cognitive Dysfunction with a site in Egypt, or all of them as a file.
02

Study summary

Cognitive technology therapies, including interactive video gaming, computer soft wares and mobile technology, have been used to implement cognitive training and rehabilitation programs. Potential advantages to using technology-based interventions include enhanced accessibility and cost-effectiveness, providing a user experience to be good communicator, immersive and comprehensive.

Read the detailed description

Aging over 60 years is associated with some progressive decline in cognitive domains, such as processing speed and executive function. A significant decline in cognitive function, particularly memory, which is an early symptom of dementia, can lead to mild cognitive impairment (MCI). Currently it is estimated that 50 million are living with dementia worldwide and nearly 10 million new cases occur every year, representing a serious public health problem. As such, the WHO has suggested that preventing cognitive decline and dementia is a global mental health priority. In addition to impacting the patient, dementia also has a significant impact on the family and society in general. Age is the biggest risk factor for the development of dementia, and aging is associated with a decline of cognitive function. Non-pharmacological interventions such as physical exercise and cognitive interventions may offer an alternative to pharmacological intervention in delaying dementia-related functional decline. Over the last decade, the accessibility and use of computers, smartphones and mobile internet has quickly expanded .

Cognitive technology therapies, including interactive video gaming, computer soft wares and mobile technology, have been used to implement cognitive training and rehabilitation programs. Potential advantages to using technology-based interventions include enhanced accessibility and cost-effectiveness, providing a user experience to be good communicator, immersive and comprehensive.

03

Conditions studied

  • Cognitive Impairment
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria

1- Age ≥ 65 years. 2- Literate with ≥ 15 years of education. 3- Older adults with mild dementia. 4- score 18-26 .( Pinto et al .,2019). 5- Android smartphone user. 6- Well ability to write and read. Exclusion criteria

  1. Major Cardiovascular events , such as Stroke or Myocardial infraction in past three months.
  2. Alzheimer's disease.
  3. Sever cognitive dementia.
  4. Sever hearing difficulty or visual disturbance.
  5. Brain injury.
  6. Limitation in communications.
  7. Chronic kidney diseases.
  8. Liver diseases.
  9. Low or high educated.
  10. Uncontrolled diabetic patients.
  11. Thyroid disturbance.
  12. Mental and psychological instability .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    group A

    (Therapy group) It will include subjects that will receive computer based cognitive therapy sessions training. omega 3 supplement .

    Behavioral: cognitive therapy

  • Experimental
    Group B

    (Smartphone group) It will include subjects that will receive home program training by using their smartphones cognitive applications . omega 3 supplement .

    Behavioral: cognitive therapy

  • Placebo comparator
    group c

    It won't receive interventions. only omega 3 supplement

    Behavioral: cognitive therapy

Interventions

  • Behavioralcognitive therapy

    intervention : group A: recive computer cognitive traing by rehacom system and omega 3 supplement . group B: recive smart phone cognitive application and omega 3 supplement . group c recive omega 3 supplement only.

    Also known as: cognitive training

06

What researchers measure

Primary outcomes

  1. Cognitive functions assessment

    Cognitive function : It was assessed by rehacom software and Montreal cognitive assessment (MoCA) which are a highly sensitive and specific screening tool for patients with impaired cognitive function. 1- Rehacom software screening: 9 screening modules detect cognitive functions: 4Attention, 2memory, 1logical reasoning and 2 visual field. Montreal test is a short in duration (10- 15 min) 30-point screening test that measures a number of cognitive domains such as visuospatial abilities, executive function, short-term memory, attention/concentration, language, abstract thinking, and orientation. . Patients with MoCA scores of less than 26 are considered cognitively impaired Arabic version was used

    Time frame: 1 year

Secondary outcomes

  1. Quality of life survey

    Quality of life : it was assessed by SF-12 health survey quality of life questionnaire. The SF-12 is a generic, standardized questionnaire used to meas- ure two components of HRQoL: physical and mental health. . It is a shorter, yet valid alternative to the most widely used health status scale: the Short-Form-36 Health Survey Questionnaire (SF-36). The SF-12 reproduces the physical and mental component summary scores (PCS/MCS) of the SF-36. In addition, as the SF-12 contains fewer questions and takes less time to complete than the SF-36, it is more appropriate for use with older adults with common geriatric diseases, such as dementia .There scores range from zero (lowest HRQoL)-100 (highest)

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Nour Ali
    Cairo, Giza 12511, Egypt
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2024, 11 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 11 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Apr 22, 2024
StartActual
Jul 1, 2023
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jun 1, 2024
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06378606
Lead sponsor
Nourhan Hesham Ali
Collaborators
Cairo University
Responsible party
Nourhan Hesham Ali (physiotherapist /Nourhan Hisham Ali, Cairo University) — Sponsor-investigator
First posted
Apr 22, 2024
Start date
Jul 1, 2023
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Apr 22, 2024

Study contacts

nourhan hisham ali
Contact
nourheshame854@gmail.com
01156860154
kareem adel mohamed
Contact
Adelkareem302@gmail.com
01068908618
ahmed mahdi ahmed
study director · Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion